Papers/PMID:32968158
Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial.
Scientific reports2020The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
calciol — increases serum 25-hydroxyvitamin D concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×14“At Month 3 and 6, there was no significant difference between thrice-weekly vs. once-monthly cholecalciferol groups (P = 0.19 and 0.40, respectively), and both groups showed higher serum 25(OH)D levels than the placebo group (P < 0.001).”
Quoted verbatim from Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial.. - Study
- RCT
- Duration
- 6 months
- Dose
- 3,000 IU thrice weekly after dialysis, or once monthly 36,000 or 45,000 IU (equivalent to 9,000 IU/week)
- Population
- Haemodialysis patients on erythropoiesis-stimulating agents in Japan; both cholecalciferol regimens (3,000 IU thrice weekly and once-monthly, equivalent to 9,000 IU/week) compared with placebo at Months 3 and 6
Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial.2020PMID:32968158Industry fundedPermalink